Alzheimer's drug shows long-term benefits in behavior and cognition. EU approval of Blarcamesine could boost its market value ...

Warren Buffett’s Berkshire Hathaway BRK.A BRK.B just filed its 13F for the first quarter of 2025. Here’s a look at the stocks ...

With its stock down 30% over the past three months, it is easy to disregard Core Laboratories (NYSE:CLB). But if ...

D2L (TSE:DTOL) has had a rough three months with its share price down 23%. However, a closer look at its sound financials might cause you to think again. Given that fundamentals usually drive ...

Through April 4th, FV has managed to claw back a chunk of that lost relative performance in 2025, with a 3.1% return vs the S ...